This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these nutrients into the body as compared to the original PreserVision AREDS 2 mini soft gel formula.(+)1
For my patients with moderate to advanced Age-related Macular Degeneration (AMD), a leading cause of vision loss in Americans ages 50 and older, I typically recommend a plan that includes a healthy diet, exercise and PreserVision AREDS 2 Formula eye vitamins to help reduce the risk of disease progression,' said
PreserVision AREDS 2 Formula eye vitamins, including the new OCUSorb formula, contain the exact nutrient formula recommended by the
We're pleased to offer eye care professionals and their patients this enhanced offering - the proven AREDS 2 formula eye vitamin with better absorbing nutrients from the patented OCUSorb technology,' said
PreserVision AREDS 2 Formula mini soft gels with OCUSorb are now available at most major retailers nationwide in the vitamin aisle or online and will replace the current PreserVision AREDS 2 Formula mini gel formula.
About AMD
AMD is a progressive eye condition that impacts central vision and is a leading cause of blindness in adults 50 years of age and older. Early-stage AMD often does not present any symptoms or changes in vision, as symptoms usually appear gradually over time. This progressive condition can impact one or both eyes, causing people to have difficulty with daily activities like driving, reading or recognizing the faces of loved ones.3
About PreserVision AREDS 2 Formula Eye Vitamins
PreserVision AREDS 2 formula eye vitamins, the most studied eye vitamin brand, contain the exact NEI-recommended formula based on the AREDS2 study. The daily dose (two capsules) of PreserVision AREDS 2 vitamins provides the exact same levels of all six clinically proven nutrients as the NEI supported formula: vitamin C (500mg), vitamin E (400 IU/180mg), lutein (10mg), zeaxanthin (2mg), zinc (80mg zinc oxide), and copper (2mg cupric oxide).
About the AREDS, AREDS2 and 10-Year Follow-on AREDS2 Study Results
The AREDS and AREDS2 studies are landmark clinical studies conducted over 20 years by the NEI. The AREDS study in 2001 demonstrated that taking a specific combination of antioxidants and zinc could help reduce the risk of progression of AMD in those with moderate to advanced AMD. In 2012, the NEI completed the AREDS2 study, which tested several changes to the formulation, such as adding omega-3 fatty acids, substituting lutein and zeaxanthin for beta-carotene, and/or reducing zinc. The current AREDS2 nutrient formula recommended by the NEI is the result of this study.
The NEI 10-Year Follow-on Study results evaluated the long-term results of participants who were involved in the AREDS2 study. Consisting of 3,883 people (6,351 study eyes) with moderate to advanced AMD over a 10-year period, the follow-on study further validates the original findings of the AREDS2 formulation with lutein and zeaxanthin, demonstrating an incremental reduction in risk of the progression to late-stage AMD.2
About
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words 'anticipates,' 'hopes,' 'expects,' 'intends,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'believes,' 'estimates,' 'potential,' 'target,' or 'continue' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in
Contact:
Email: arthur.shannon@bausch.com
(C) 2023 Electronic News Publishing, source